Let's go through the references for the so called metaanalysis:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30084-0/fulltext Data in the above trial included MPC patients, therefore should not be included in the analysis. (Isn't it wonderful reading trial results from a double blind randomised trial?)
https://www.sciencedirect.com/science/article/pii/S0923753419349476 Again, included MPC patients (some 80%). (Is this how Oncosil derived the p<0.001?)
https://www.oncotarget.com/article/22795/ Sorry, 70% of patients were MPC. In the sub-analysis of the patients with LAPC (10 patients): OS: 16.7; PFS: 9.6 (FOLFIRINOX trial/ so comparable but only for the LAPC subset patient population).
https://www.ejcancer.com/article/S0959-8049(18)30966-3/fulltext WOW... A RELEVANT REFERENCE!!! this trial looked at abraxane + gemcitabine (control) vs abraxane + gemcitabine + cisplatin + capecitabine. (Panco looked at oncosil + abraxane + gemcitabine)
The so called meta-analysis was compared to hundreds of irrelevant trials, so you need to really look up the gems in there that use the same treatment regimen (FOLFIRINOX or abraxane + gemcitabine based trials... ie. the trials in the n> column (there's plenty of them))
Wait a moment... both arms of this study beat Panco on resection rate but the poster shows n> as only 1.
https://link.springer.com/article/10.1007%2Fs10637-018-0691-9 OS: 20.7; PFS: 10.7 gemcitabine + leucavorin + S-1. Wow, neat combo. It beat Panco on resection rates too... why on earth is the poster only showing n>1. Oh yeah, they cut the number of comparator studies for that table :/
https://link.springer.com/article/10.1007%2Fs12032-018-1158-8 part of GLS trial above.
https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2018-0900 Seriously! the MPC component was 57%. Even so, OS: 17.7; PFS: 7.4. S‐1 + oxaliplatin + irinotecan. When we separate the MPC/LAPC, then OS: 10 for MPC and 22 for LAPC patients! That's right... recent combination therapy trials are hitting 20 plus months survival.
You really think 15-16 months survival for oncosil + gemcitabine + abraxane OR oncosil + FOLFIRINOX is going to cut it? when we know gemcitabine + abraxane (without oncosil) trials are hitting the 15-20 month survival range... e.g. https://link.springer.com/article/10.1245/s10434-018-6807-9 (18m OS) e.g. https://www.sciencedirect.com/science/article/abs/pii/S2468125319303279 (18.8m OS) and FOLFIRINOX/ combinations thereof are hitting the 20 month plus survival range.
I thought this announcement was an update on the Panco trial... guess not.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)